Benzinga | May 17, 2021 08:12AM EDT

Aeterna Zentaris Announces Start Of Preclinical Development Of Macimorelin At The University Of Queensland As A Potential New Treatment Option For Patients With Amyotrophic Lateral Sclerosis

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the "Company" or "Aeterna Zentaris"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). The preclinical development program is part of the recently executed Material Transfer Agreement (MTA) with The University of Queensland ("The University").